Comparison of efficacy of Ingakort, Beclomethazone-easyhaler and Flixotide-diskus in their sequential administration for bronchial asthmatic patients
Abstract
Twenty patients (12 females and 8 males) suffering from stable moderate non-atopic bronchial asthma and receiving Ingakort in the supporting dose 1000 to 1500 meg daily (in average 1150 meg daily) during 6 to 8 months, were moved up to 4-week treatment with 600 to 800 meg daily of dry powders of Beclomethazoneeasyhaler (660 meg daily in average) and 500 meg daily of Flixotide-diskus sequentially. Dynamics of clinical symptoms in marks, need for beta-2-agonists, pulmonary function parameters, airways obstruction reversibility tested by response to Salbutamol and local adverse events were investigated.
The reliable regression of asthma clinical symptoms was revealed in 2 weeks of treatment with dry powders of Beclomethazone and Flixotide and that of need for beta-2-agonists was obtained in 4 weeks. This effect was greater against the treatment with Flixotide-diskus background. The large bronchi’s passability was improved but FEV1, FEF50 and FEF25 changes were not significant. No local adverse events were revealed.
The results obtained confirm the comparability of the doses mentioned above of Ingakort, Beclomethazone and Flixotide, high efficacy and safety of their powdered forms as well.
About the Authors
A. N. Tsoy
ММА им. И.М. Сеченова
Russian Federation
Russian Federation
F. I. Abazova
ММА им. И.М. Сеченова
Russian Federation
Russian Federation
M. S. Gafurov
ММА им. И.М. Сеченова
Russian Federation
Russian Federation
O. A. Shor
ММА им. И.М. Сеченова
Russian Federation
Russian Federation
References
1. Бронхиальная астма. Глобальная стратегия. Основные направления лечения и профилактики астмы. Совместный доклад Национального института Сердце, Легкие, Кровь и Всемирной организации здравоохранения. Русская версия под общей редакцией академика А.Г. Чучалина / / Пульмонология.— 1996.— Прил.— С. 1 — 157.
2. Цой A.H., Гафуров М.С. Эффективность и безопасность применения препарата пульмикорт турбухалер 1000 мкг/сутки у больных с обострением бронхиальной астмы, ранее не получавших ингаляционных глюкокортикостероидов/ / Там же.— 1999.— № 1.— С. 71— 76.
3. Brattsand R. What factors determine anti-inflammatory activity and selectivity of inhaled corticosteroids?// Eur. Respir. Rev.— 1997.— Vol. 7, N 49.— P. 356— 361.
4. British Thoracic Society. The British guidelines on asthma management./ / Thorax.— 1997.—Vol. 52.— Suppl. 1.— P. 1—21.
5. Edsbacker S., Szefler S.J. Glucocorticoid pharmacokinetics: principles and clinical applications// Schleimer R.P., Busse W.W., O'Byrne P.M., editors. Inhaled Glucocorticoids in Asthma.— New York: Marsell Dekker, 1997.— P.381—426.
6. Falcoz C., Mackie A.E., Moss J. et al. Pharmacokinetics of fluticasone propionate inhaled from the Disckhaler and the Diskus after repeat doses in healthy subjects and asthmatic patients//J. Allergy Clin. Immunol.— 1997.—Vol.99,.— P.505.
7. Holliday S.М., Faulds D., Sorkin E.M. Inhaled fluticasone propionate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma// Drugs — 1994.— Vol. 47.— P.356—361.
8. National Asthma Education and Prevention Program. Expert Panel Report, No.2: Guidelines for the Diagnosis and Management of Asthma. US Dept 7, Health & Human Services, NIH Publication.— Bethesda, 1997.— N 97—4051 A.— P .l—50
9. Newman S.P., Brown J., Steed K.P. et al. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines. Comparison of respimat with conventional metered-dose inhalers with and without spaser devices// Chest.— 1998.— Vol. 113, N 4.— P.957— 963.
10. Pauwels R.A., Yernault J.C., Demedts M.G. et al. Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma// Am. J. Respir. Crit. Care Med.— 1998.— Vol. 157.— N4.— P.827—832.
11. Selroos O., Backman R., Forsen K.O. et al. Local side-effects during 4-year treatment with inhaled corticosteroids: a comparison between pressurized metered-dose inhalers and turbuhaler// Allergy.— 1994.— Vol. 49.— P.888—890.
12. Sont J.K., Willems L.N.A., Euertse C.E. et al. Long-term management of asthma: is it worth it to treat bronchial hyperresponsiveness (BHR) beyond clinical symptoms and lung function (abstract)// Am. J. Respir'. Crit. Care Med.— 1997. — Vol. 155.— A203.
13. Thorsson L., Dahlstrom K., Edsbacker S. et al. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects// Br J Clin Pharmacol.— 1997.— Vol.43.— P. 155— 161.
Review
For citations:
Tsoy A.N., Abazova F.I., Gafurov M.S., Shor O.A. Comparison of efficacy of Ingakort, Beclomethazone-easyhaler and Flixotide-diskus in their sequential administration for bronchial asthmatic patients. PULMONOLOGIYA. 2000;(2):40-46. (In Russ.)
Views:
189
Email this article 